USRM alleges 10,000 kit sales of Adipocell product

U.S Stem Cell, Inc. claimed to be a leader in the development of proprietary stem cell therapies asserted accomplishing the target of 10,000 kit sales of proprietary Adipocell product, a manifestation of 700 + physicians offering USRM’s stem cell products and services. Adipocell enables physicians to separate potent stem cells from patient’s (autologous) fat cells, which are later reinserted in a minimally invasive procedure. Stem cells are an essential component of the body’s ability to regenerate itself thereby yielding trendy in the mainstream field of regenerative medicine.

USRM is primarily into marketing and manufacturing an autologous adipose/stem cell separation kit. Autologouss cells are alleged to be more compatible  in alleviating destruction caused thus dwindling the adverse effect yielding recovery. Having initiated a training program for physicians who intend to learn ways to offer stem cell therapy to their patients involving a 2 day, interactive hands-on training course at USRM’s Sunrise, Florida-based Clinic.

Mike Tomas, President and CEO of U.S. Stem Cell, Inc stated “We are dedicated and proud to lead the way on a global scale for the emergence of this novel therapeutic.”

Image Source: U.S Stem Cell, Inc.